InnoCare Pharma Limited (HKG:9969)
Hong Kong · Delayed Price · Currency is HKD 16.90
+0.04 (0.24%)
Aug 29, 2025, 4:08 PM HKT
InnoCare Pharma Revenue
InnoCare Pharma had revenue of 350.17M CNY in the quarter ending June 30, 2025, with 37.91% growth. This brings the company's revenue in the last twelve months to 1.32B, up 69.22% year-over-year. In the year 2024, InnoCare Pharma had annual revenue of 1.01B with 36.68% growth.
Revenue (ttm)
1.32B CNY
Revenue Growth
+69.22%
P/S Ratio
23.26
Revenue / Employee
1.21M CNY
Employees
1,089
Market Cap
33.68B HKD
Revenue Chart
* This company reports financials in CNY.
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 1.01B | 270.91M | 36.68% |
| Dec 31, 2023 | 738.54M | 113.13M | 18.09% |
| Dec 31, 2022 | 625.40M | -417.63M | -40.04% |
| Dec 31, 2021 | 1.04B | 1.04B | 76,368.70% |
| Dec 31, 2020 | 1.36M | 117.00K | 9.38% |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| BeOne Medicines | 35.81B |
| Hansoh Pharmaceutical Group Company | 14.45B |
| JD Health International | 71.34B |
| Innovent Biologics | 12.52B |
| Sino Biopharmaceutical | 33.49B |
| Akeso | 2.75B |
| WuXi Biologics | 21.98B |
| CSPC Pharmaceutical Group | 28.49B |